Uterine Fibroid Treatment Device Market –By Technology, By Treatment- Global Forecast, 2025 - 2034

Uterine Fibroid Treatment Device Market Size

The global uterine fibroid treatment device market size was valued at USD 7 billion in 2024. The market is anticipated to grow from USD 7.4 billion in 2025 to USD 13.8 billion in 2034, growing at a CAGR of 7.2% from 2025 to 2034. The uterine fibroids treatment devices market is experiencing steady growth due to the rising occurrence of fibroids among women of reproductive age, creating a greater demand for reliable and safe treatment methods. Increased awareness of minimally invasive and uterus-preserving procedures, along with the growing use of advanced medical technologies, is further stimulating the uptake of these treatment solutions.
 

Growing development within the uterine fibroids treatment drug (the market of which was valued to be USD 1.7 billion in 2022) can be the result of expanding prevalence of uterine fibroids among women of reproductive age. Uterine fibroids are benign tumors of the uterus that can cause indications such as heavy menstrual bleeding (HMB), pelvic pressure, and infertility, affecting quality of life.
 

Uterine Fibroid Treatment Device Market Trends

• The market has witnessed notable advancements in recent years, fueled by the emergence of innovative, minimally invasive technologies that improve both treatment safety and effectiveness. These modern solutions employ energy-based techniques such as radiofrequency ablation (RFA), magnetic resonance-guided focused ultrasound (MRgFUS), and uterine artery embolization (UAE) to manage fibroids while preserving the uterus.
   
• For example, Gynesonics' Sonata System combines real-time intrauterine ultrasound with targeted radiofrequency ablation, which provides a non-invasive, uterus-conserving approach that minimizes recovery time and lowers the risk of complications when compared to traditional surgeries like hysterectomy or myomectomy.
   
• These technological improvements are enhancing clinical outcomes by offering safer, patient-friendly alternatives to address heavy menstrual bleeding, pelvic discomfort, and fertility concerns, all the factors contributing significantly to market expansion.
   
• Moreover, minimally invasive treatments are gaining popularity due to their advantages, including reduced postoperative discomfort, shorter hospital stays, and faster recovery periods when compared to open surgeries. Technologies like MRgFUS utilize focused ultrasound waves to thermally ablate fibroid tissue, enabling patients to return to daily activities in a short time. Similarly, RFA devices from companies such as Hologic and Medtronic deliver controlled energy with minimal surrounding tissue damage, increasing treatment precision and safety.
   

Uterine Fibroid Treatment Device Market Analysis

In 2021, the global market was valued at USD 5.9 billion. The following year, it saw a slight increase to USD 6.2 billion in 2022, and by 2023 and 2024, the market further climbed to USD 6.6 billion and USD 7 billion respectively. Based on technology, the global market is segmented into surgical techniques, laparoscopic techniques, ablation techniques, and embolization techniques. The surgical techniques segment accounted for the highest market share and was valued at USD 2.9 billion in 2024.
 

• Surgical techniques are designed to remove fibroids or the uterus itself, depending on the severity and nature of the condition. These include procedures such as myomectomy and hysterectomy, which are recommended for women with large, multiple, or symptomatic fibroids.
   
• The significant market share of surgical techniques is stimulated by their wide acceptance among both patients and healthcare professionals and also due to their high clinical success rate, long-term relief from symptoms
   
• The expanding healthcare infrastructure, and comprehensive insurance coverage combined with greater accessibility to skilled surgeons, further contribute to the continued dominance of this segment.
   
• In addition to the benefits of the devices, the factors such as rising occurrence of menorrhagia, and various other gynecologic disorders further contributes to the expansion of the segment.

Based on treatment, the global uterine fibroid treatment device market is categorized into invasive treatment, minimally invasive treatment, and non-invasive treatment. The invasive treatment segment dominated the market in 2024 and is anticipated to witness growth at a CAGR of 7.1%.
 

• The invasive treatment segment represents a major portion of the market, largely because of its proven ability to address severe and complicated fibroid cases using procedures such as open myomectomy and hysterectomy. These surgical methods deliver lasting symptom relief, especially for women with large, numerous, or deeply located fibroids.
   
• Unlike minimally or non-invasive procedures, invasive procedures regularly offer a more conclusive treatment, successfully tending to issue such as excessive menstrual bleeding, pelvic pain, and fertility complications. This alternative is generally chosen when less aggressive medications fail to convey satisfactory outcomes.
   
• Numerous patients turn to invasive surgery after encountering limited success with alternative approaches. The strong success rates of these surgeries, alongside advancements in surgical practices, have contributed to their developing acknowledgment among both medical experts and patients. With continued adoption of progressed surgical frameworks, the reliability and safety of invasive medications are anticipated to further improve.

The North America uterine fibroid treatment device market dominated the global market with a market share of 42.5% in 2024. The market is driven by the increasing prevalence of uterine fibroids. Advancements in technology and a growing focus on early and accurate diagnosis also support market growth.
 

The U.S. market was valued at USD 2.5 billion and USD 2.6 billion in 2021 and 2022, respectively. The market size reached USD 3 billion in 2024, growing from USD 2.8 billion in 2023.
 

• The accessibility of highly skilled healthcare experts with specialization in womens wellbeing and gynecology is essentially contributing to the market development within the U.S.
   
• For instance, in May 2022, the U.S. Bureau of Labor Statistics reported the presence of approximately 19,820 obstetricians and gynecologists within the country.
   
• Additionally, according to a study in NIH in 2023, around 200,000 hysterectomies, 30,000 myomectomies, and thousands of uterine artery embolization and high-intensity focused ultrasound procedures are performed each year for the removal or destruction of fibroids.
   
• Moreover, technological advancements in uterine fibroid treatment devices, alongside progressed education and awareness about minimally invasive methods for the treatment of gynecological disorders, are further fueling the development of the market within the country.
   

Europe uterine fibroid treatment device market accounted for USD 1.9 billion in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• Expanding awareness among European women with respect to reproductive wellbeing, coupled with enhanced access to gynecological care, is anticipated to bolster the development of the market across the region.
   
• In addition, the expanding awareness regarding progressed removal procedures, especially among mature women aged 35 to 45, is further solidifying the development of the market within the region.
   
• For instance, as per the data from PubMed, ablation technique is rapidly becoming a popular procedure, especially among women aged 35 to 45 years. The increasing awareness of the procedure's benefits in this age group is stimulating its adoption.
   

Germany uterine fibroid treatment device market is anticipated to witness considerable growth over the analysis period.
 

• The country’s well-established practices and research institutions, beside its emphasis on high-quality medical equipment, contribute to the widespread adoption of uterine fibroid treatment devices.
   
• The rising predominance of uterine fibroids among women, together with developing awareness of accessible treatment choices such as radiofrequency ablation and uterine artery embolization, is driving demand for progressed therapeutic arrangements.
   
• Moreover, Germanys high healthcare expenditure and the availability of well-trained healthcare experts support the uptake of both minimally invasive and invasive treatment innovations, upgrading patient care.
   
• Also, role of Germany, as a center for advancement in diagnostics further solidifies its position as a pioneer within the market, catering to both domestic and international demand for reliable and efficient solutions.
   

The Asia Pacific uterine fibroid treatment device market is anticipated to grow at the highest CAGR of 7.9% during the analysis timeframe.
 

• The market in the Asia Pacific region is growing rapidly due to the rising prevalence of uterine fibroids and increasing preference for minimally invasive treatment options.
   
• Countries such as China, India and Japan are adopting technology at a faster rate owing to the enhanced demand for better services.
   
• Additionally, rapid rise in the number of clinics and hospitals coupled with government policies aimed at women’s health care contribute to the rapid growth of the market in the region.
   

China uterine fibroid treatment device market is predicted to grow significantly over the forecast period.
 

• Uterine fibroids are predominant among Chinese women of reproductive age, with studies (published by British Medical Journal in January 2025) demonstrating a prevalence rate of approximately 25.18% among women aged 15-49 years.
   
• The frequency and predominance of uterine fibroids increase with age, peaking in women matured 40-54 years, where predominance rates range from 38.60% to 45.38%.
   
• Furthermore, the presence of a large number of local manufacturers in the country also enhances market growth.
   

Brazil is experiencing significant growth in the Latin America uterine fibroid treatment device market due to the increasing demand for advanced tools in gynecological care.
 

• Brazil is witnessing a growing prevalence of uterine fibroids among women of reproductive age, contributing to increased demand for effective treatment options.
   
• The country’s expanding healthcare infrastructure and rising awareness about women’s health issues are driving the adoption of advanced uterine fibroid treatment devices.
   
• According to a 2023 NIH study, Brazil recorded one of the highest increase in age-standardized uterine fibroid incidence rates.
   
• Additionally, ongoing investments in medical technology and a growing middle-class population with higher healthcare spending power are expected to boost the demand for advanced uterine fibroid treatment devices in Brazil.
   

Saudi Arabia uterine fibroid treatment device market is poised to witness substantial growth in Middle East and Africa market during the forecast period.
 

• The growth of the market is highly influenced by the increasing investment in healthcare infrastructure, including advanced medical device, such as uterine fibroid treatment devices, which is propelling the growth of the market in the country.
   
• For instance, Saudi Arabia's Vision 2030 includes significant investments in healthcare infrastructure, which are aimed at enhancing the quality and accessibility of medical services including uterine fibroid treatment across the country.
   
• Thus, these initiatives is aimed to enhance the quality and adoption of high quality medical technologies such as uterine fibroid treatment devices, establishing the nation as a significant contributor in the healthcare environment of the Middle East and Africa.
   

Uterine Fibroid Treatment Device Market Share

Competition in the market is characterized by a mix of well-established multinational corporations, innovative emerging firms, and regional players striving to increase their market share. Leading companies such as Medtronic, Boston Scientific, Insightec, CooperSurgical Inc., Hologic, and Gynesonics collectively account for approximately 35% of the global market.
 

Additionally, there are several local and regional players operating in the market who are boosting competition by providing affordable options at lower costs. These players are also involved in several strategies such as mergers, acquisitions, and novel product launches to expand their product offerings.
 

Uterine Fibroid Treatment Device Market Companies

Few of the prominent players operating in the industry include:

• Boston Scientific
• Canyon Medical
• Conmed
• CooperSurgical
• Hologic
• Insightec
• Johnson & Johnson (Ethicon)
• Karl Storz
• Medtronic
• Merit Medical Systems
• Minerva Surgical
• Nesa Medtech
• Olympus
• Shenzhen Mindray Bio-Medical Electronics
• Terumo Corporation
   
• Medtronic has a strong global presence, with its products being sold in more than 150 countries. Medtronic provides the sole RFA device for laparoscopic fibroid ablation which has received FDA approval. The device integrates treatment with ultrasound view, treating only the affected areas.
   
• CooperCompanies has strong financial growth, reporting fourth quarter 2024 revenues of USD 1,018.4 million, marking a 10% increase compared to the same quarter in the previous year.
   
• Boston Scientific through surgical expansion into women’s health and minimally invasive gynecological procedures, along with the purchase of nVision Medical, strategically positioned itself as a strong market player in the market.
   

Uterine Fibroid Treatment Device Industry News

• In January 2025, Hologic announced to acquire Gynesonics, for about USD 350 million. Gynesonics, a privately owned company, focuses on creating women's healthcare devices. Gynesonics possesses and markets the Sonata System, an ultrasound guided intrauterine diagnostic and therapeutic system which enables the intrauterine imaging and transcervical treatment of some symptomatic fibroids including those causing heavy menstrual bleeding.
   
• In September 2024, Gynesonics introduced its SMART OS 2.4 software for the Sonata System, enhancing the treatment of symptomatic uterine fibroids by extending ablation size range and improving workflow precision, control, and flexibility for healthcare providers.
   
• In July 2024, Nesa Medtech received U.S. FDA clearance for its Fibroid Mapping Reviewer Application (FMRA), a diagnostic tool designed to assist physicians in determining the location and dimensions of uterine fibroids, thereby enhancing the planning of minimally invasive treatments.
   
• In November 2022, Olympus announced the release of the moresolution Power Morcellator. The Morcellator is manufactured by TROKAMED GmbH and distributed in the U.S. by Olympus America, Inc. Olympus’s America has extensive marketing agreements having the sole proprietary distributorship. The Morcellator is crafted for advanced gynecologic surgery involving removal of petrified soft tissue bones.
   

The uterine fibroid treatment device market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Technology

• Surgical techniques
  • Hysterectomy
  • Myomectomy
• Laparoscopic techniques
  • Laparoscopic myomectomy
  • Myolysis
• Ablation techniques
  • Microwave ablation
  • Hydrothermal ablation
  • Cryoablation
  • Ultrasound ablation
    • High intensity focused ultrasound (HIFU)
    • MRI-guided focused ultrasound (MRGFUS)
• Embolization techniques

Market, By Treatment

• Invasive treatment
• Minimally invasive treatment
• Non-invasive treatment

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE